NCT06428045 2025-06-22
STARLITE
University of Miami
Phase 1 Recruiting
Clinical Trials
9 trialsNCT05679388 2024-09-19
A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients
University of Chicago
Phase 1 Terminated
NCT03066154 2024-06-03
DOP
The Netherlands Cancer Institute
Phase 1 Terminated
NCT01165645 2022-12-01
Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma
Mayo Clinic
Phase NA Withdrawn
NCT02770378 2021-10-05
A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma
University of Ulm
Phase 1/2 Completed
NCT02948283 2021-02-12
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
City of Hope Medical Center
Phase 1 Completed
NCT01009437 2017-12-05
Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT00444379 2014-08-20
ARKS
University of California, San Francisco
Phase 4 Completed
NCT01095094 2013-06-10
Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma
Case Comprehensive Cancer Center
Phase 2 Terminated